# EDGAR Filing Document

**Accession Number:** 0001736297
**File Stem:** 0001736297-25-000097
**Filing Date:** 2025-8
**Character Count:** 38532
**Document Hash:** d6c69881bfe3e918f7b05a167af1f769
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001736297-25-000097.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001736297-25-000097

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250805

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astera Labs, Inc.
- **CENTRAL INDEX KEY:** 0001736297
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 823437062
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41979
- **FILM NUMBER:** 251185017

**BUSINESS ADDRESS:**
- **STREET 1:** 2345 NORTH FIRST STREET
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95131
- **BUSINESS PHONE:** 408-242-7319

**MAIL ADDRESS:**
- **STREET 1:** 2345 NORTH FIRST STREET
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95131

?xml version='1.0' encoding='ASCII'? alab-20250805

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): August 5, 2025** 

**Astera Labs, Inc.**

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41979** | **82-3437062** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**2345 North First Street,** 

 **San Jose, CA 95131**

**(Address of principal executive offices) (Zip Code)** 

**Registrant's telephone number, including area code: (408) 766-3806**

**Not applicable** 

**(Former name or former address, if changed since last report.)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of**<br>**each class** | **Trading**<br>**Symbol** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, par value $0.0001 per share** | **ALAB** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition** 

On August 5, 2025, Astera Labs, Inc. (the "Company") issued a press release regarding its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

**(d) Exhibits.** 

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description of Exhibit</u>** |
| 99.1 | <u>[Press release issued by Astera Labs, Inc. dated August 5, 2025.](q225exhibit991.htm)</u> |
| 104 | <u>Cover Page Interactive Data File (Cover page XBRL tags are embedded within the Inline XBRL document)</u> |

---

------

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: August 5, 2025 | Astera Labs, Inc. |
|  | By: <u>/s/ Michael Tate</u>  |
|  | Name: Michael Tate |
|  | Title: Chief Financial Officer |

---

## Exhibit 99.1

Exhibit 99.1

![asteralabsa.jpg](asteralabsa.jpg)

**IR CONTACT:** Leslie Green

leslie.green@asteralabs.com

**Astera Labs Announces Financial Results for the Second Quarter of Fiscal Year 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Record quarterly revenue of $191.9 million, up 20% QoQ and 150% YoY, and record operating cash flow generation of $135 million* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Industry leading PCIe 6 connectivity portfolio ramping in volume on customized rack-scale AI systems*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Scorpio fabric switch design wins expand across multiple new customers and applications*

**SAN JOSE, CA, U.S. – August 5, 2025** – Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced preliminary financial results for the second quarter of fiscal year 2025, ended June 30, 2025.

"Astera Labs delivered strong financial results in Q2 with sequential revenue growth of 20 percent, driving meaningful upside to earnings and cash flow from operations," said Jitendra Mohan, Astera Labs' Chief Executive Officer. "During Q2, we successfully executed the next step in our growth journey by ramping our PCIe 6 product portfolio into volume production for customized rack-scale AI systems and added multiple new design wins for our Scorpio Fabric Switches. We also saw strong demand for our signal conditioning portfolio driven by PCIe scale-up and Ethernet scale-out connectivity applications in custom ASIC platforms. Astera Labs is at the forefront of an AI infrastructure transformation, and we are accelerating our investments to realize our vision of rack-scale connectivity in next-generation AI systems."

**Second Quarter 2025 Financial Highlights** 

GAAP Financial Results:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $191.9 million, up 20% sequentially and up 150% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP gross margin of 75.8%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP operating income of $39.8 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP operating margin of 20.7%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP net income of $51.2 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP diluted earnings per share of $0.29

Non-GAAP Financial Results (excluding the impact of stock-based compensation expense and the income tax effects of non-GAAP adjustments):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP gross margin of 76.0%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP operating income of $75.2 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP operating margin of 39.2%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP net income of $78.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP diluted earnings per share of $0.44

------

**Q2 2025 and Recent Business Highlights** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expanded collaboration with NVIDIA to advance the NVLink Fusion ecosystem and expand the options available for hyperscalers to deploy high-performance, scale-up networks based on NVIDIA NVLink technology. Astera Labs will provide NVLink connectivity solutions to further expand our Intelligent Connectivity Platform, which seamlessly integrates PCIe, CXL, and Ethernet silicon and hardware solutions with the COSMOS suite to enhance data center visibility while optimizing system performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hosted comprehensive Ultra Accelerator Link ("UALink") public webinar to discuss the fundamentals of the UALink technology, outline the UALink market opportunity, and demonstrate how Astera Labs is uniquely positioned to help proliferate the open, memory-semantic fabric that delivers high-bandwidth, low latency, and broad interoperability. As a Promoter Member of the UALink Consortium, Astera Labs is working closely with industry partners to advance this open connectivity ecosystem that helps unleash the next generation of performant, efficient, and scalable AI platforms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Joined AMD on stage for their Advancing AI 2025 keynote presentation as a trusted partner to help showcase the ecosystem collaborating to power the next era of AI. Together, the two companies highlighted how UALink connectivity solutions will be critical for enabling innovative scale-up architectures for the next generation of AI infrastructure. UAL represents the only open standard designed specifically for scale-up applications and combines the best of many protocols to provide a fast and efficient architecture supported by a broad ecosystem to deliver choice and flexibility to customers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced partnership with high-performance ASIC leader, Alchip Technologies, to advance the silicon ecosystem for AI rack-scale infrastructure through the seamless integration of purpose-built compute and connectivity solutions. The collaboration combines Alchip's custom ASIC development capabilities with Astera Labs' comprehensive connectivity portfolio to deliver validated and interoperable solutions for hyperscalers building next-generation AI infrastructure.

**Third Quarter of Fiscal 2025 Financial Outlook**

Based on current business trends and conditions, Astera Labs estimates the following:

GAAP Financial Outlook:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue within a range of $203 million to $210 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP gross margin of approximately 75%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP operating expenses within a range of approximately $116 million to $120 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP tax rate of approximately 10%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP diluted earnings per share in a range of approximately $0.23 to $0.24 on weighted-average diluted shares outstanding of approximately 180 million

Non-GAAP Financial Outlook (excluding the impact of stock-based compensation expense and the income tax effects of non-GAAP adjustments):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP gross margin of approximately 75%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP operating expenses within a range of approximately $76 million to $80 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP tax rate of approximately 20%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP diluted earnings per share in a range of approximately $0.38 to $0.39 on non-GAAP weighted-average diluted shares outstanding of approximately 180 million

------

**Earnings Webcast and Conference Call**

Astera Labs will host a conference call to review its financial results for the second quarter of fiscal 2025 and to discuss our financial outlook today at 1:30 p.m. Pacific Time. Interested parties may join the conference call by dialing 1-800-715-9871 and using conference ID 5908687. The call will also be webcast and can be accessed at the Astera Labs website at https://ir.asteralabs.com/. The webcast will be recorded and available for replay on the company's website for the next six months.

**Discussion of Non-GAAP Financial Measures**

We use certain non-GAAP financial measures, including those concerning our financial outlook, to supplement the performance measures in our consolidated financial statements, which are presented in accordance with GAAP. A reconciliation of these non-GAAP measures to the closest GAAP measure can be found later in this release. The timing and impact of any adjustments to arrive at the corresponding GAAP financial measures concerning our financial outlook are inherently dependent on future events that are typically uncertain or that may be outside of our control. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, non-GAAP pro forma diluted earnings per share, and non-GAAP pro forma weighted-average share count. We use these non-GAAP financial measures for financial and operational decision-making and as a means to assist us in evaluating period-to-period comparisons. By excluding certain items that may not be indicative of our recurring core operating results, we believe that, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, non-GAAP pro forma diluted earnings per share, and non-GAAP pro forma weighted-average share count provide meaningful supplemental information regarding our performance. Accordingly, we believe these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by our institutional investors and the analyst community to help them analyze the health of our business. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

We adjust the following items from one or more of our non-GAAP financial measures:

<u>Stock-based compensation expense</u> 

We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, companies calculate non-cash stock-based compensation expense using a variety of valuation methodologies and subjective assumptions. Moreover, stock-based compensation expense is a non-cash charge that can vary significantly from period to period for reasons that are unrelated to our core operating performance, and therefore excluding this item provides investors and other users of our financial information with information that allows meaningful comparisons of our business performance across periods.

<u>Employer payroll taxes related to stock-based compensation resulting from our IPO</u> 

We exclude employer payroll taxes related to the time-based vesting and net settlement of restricted stock units in connection with our initial public offering (the "IPO"), because this does not correlate to the operation of our business. We believe that excluding this item provides meaningful supplemental information regarding operational performance given the amount of employer payroll tax-related items on employee stock transactions was immaterial prior to our IPO.

------

<u>Income tax effect</u>

This represents the impact of the non-GAAP adjustments on an after-tax basis and one-off discrete tax adjustments that are unrelated to our core operating performance in connection with the presentation of non-GAAP net income and non-GAAP net income per diluted share. This approach is designed to enhance investors' ability to understand the impact of our non-GAAP tax expense on our current operations, provide improved modeling accuracy, and substantially reduce fluctuations caused by GAAP to non-GAAP adjustments.

<u>Non-GAAP pro forma weighted-average shares to compute non-GAAP pro forma net income per share</u> 

We present non-GAAP pro forma weighted-average shares, assuming our redeemable convertible preferred stock is converted from the beginning of each respective periods presented, to provide meaningful supplemental information regarding EPS trend on a consistent basis. All of our outstanding redeemable preferred stock converted into the equivalent number of shares of common stock in connection with our IPO.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements based on Astera Labs' current expectations. The words "accelerating," "advance," "beginning," "believe," "confidence," "committed," "continue," "deliver," "enable," "estimate," "expand," "expect," "goal," "guidance," "intend," "look," "may," "momentum," "on track," "opportunities," "proliferate," "prospects," "provide," "represent," "roadmaps," "upside," "vision," "will," and similar phrases as they relate to Astera Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Astera Labs as of August 5, 2025, and are subject to various assumptions, beliefs, risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements include, but are not limited to, statements regarding our future business, operating results, cash flow, financial position and guidance (and any underlying drivers), including for the third quarter of fiscal 2025; our business strategy, plans and market opportunities, including the expected catalysts, our rack scale connectivity vision, our associated investments, our growth profile and our ability to further build upon the new revenue base, expand our product offerings, increase our market opportunity, remain at the forefront of an AI infrastructure transformation, and scale our connectivity platform; our objectives for future operations; our production, development, shipping and delivery of, activity, applications and demand for, as well as absolute and relative revenue and growth (including the drivers) from, existing, new, growing or enhanced products such as our PCIe 6 connectivity portfolio, signal conditioning portfolio, and Scorpio P-Series Smart Fabric Switches and the performance and results of those products for our customers; the timing, impact and proliferation of different connectivity standards; the plans and potential success of our announced and ongoing collaborations, partnerships and strategic relationships; our competitive positioning and the impacts thereof; our R&D and strategic IP plans; and future industry and macroeconomic conditions, events and trends such as in cloud and AI infrastructure as well as our preparedness and solutions for them. A variety of risks and factors that are beyond our control could cause actual results to differ materially from those in the forward-looking statements including, without limitation: the competitive and cyclical nature of the semiconductor industry; the concentration of our customer base; the changes in demand for AI; the macroeconomic and/or geopolitical environment, including economic uncertainty and volatility in the capital markets; risks that demand for our products and the supply chain may be adversely affected, including by the imposition of tariffs by the United States or any other jurisdiction and any corresponding retaliatory tariffs, changes in political policies, military conflict (such as between Russia/Ukraine and Israel/Hamas), terrorism, sanctions or other geopolitical events globally (including conflict between Taiwan and China); quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with managing international activities (including trade barriers, particularly with respect to China); absence of long-term commitments from customers; risks that Astera Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; stock price volatility; information technology risks, including cyber-attacks against Astera Labs' products and its networks; and other risks and uncertainties that are detailed under the caption "Risk Factors" and elsewhere in our Annual

------

Report on 10-K, as filed with the Securities and Exchange Commission (the "SEC") on February 14, 2025, and in subsequent Quarterly Reports on Form 10-Q filed with the SEC and the other SEC filings and reports Astera Labs may make from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor(s) may cause actual results or outcomes to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not unduly rely on any of the forward-looking statements. Astera Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

**About Astera Labs** 

Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions grounded in open standards. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. Discover more at www.asteralabs.com.

------

**ASTERA LABS, INC.** 

**CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **June 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $162328 | $79551 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 902758 | 834750 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 24318 | 38811 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 58602 | 43215 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 32742 | 16652 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1180748 | 1012979 |
| Property and equipment, net | 62075 | 35651 |
| Other assets | 28582 | 5878 |
| Total assets | $1271405 | $1054508 |
| **Liabilities and Stockholders' Equity** | **Liabilities and Stockholders' Equity** | **Liabilities and Stockholders' Equity** |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $31573 | $26918 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 74810 | 59624 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 106383 | 86542 |
| Other liabilities | 29308 | 3167 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 135691 | 89709 |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock | 17 | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1258581 | 1173153 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 2874 | 426 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (125758) | (208796) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1135714 | 964799 |
| Total liabilities and stockholders' equity | $1271405 | $1054508 |

---

------

**ASTERA LABS, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)**

**(In thousands, except per share amounts)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **June 30,<br>2025** | **March 31,<br>2025** | **June 30,<br>2024** | **June 30,<br>2025** | **June 30,<br>2024** |
| Revenue | $191925 | $159442 | $76850 | $351367 | $142108 |
| Cost of revenue | 46362 | 40031 | 16996 | 86393 | 31734 |
| Gross profit | 145563 | 119411 | 59854 | 264974 | 110374 |
| Operating expenses |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 66724 | 64554 | 40089 | 131278 | 93647 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 18609 | 21702 | 22076 | 40311 | 77586 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 20456 | 21870 | 22036 | 42326 | 46455 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 105789 | 108126 | 84201 | 213915 | 217688 |
| Operating income (loss) | 39774 | 11285 | (24347) | 51059 | (107314) |
| Interest income | 10885 | 10432 | 10264 | 21317 | 12818 |
| Income (loss) before income taxes | 50659 | 21717 | (14083) | 72376 | (94496) |
| Income tax (benefit) provision | (560) | (10102) | (6537) | (10662) | 6045 |
| Net income (loss) | $51219 | $31819 | $(7546) | $83038 | $(100541) |
| Net income (loss) per share attributable to common stockholders: | Net income (loss) per share attributable to common stockholders: | Net income (loss) per share attributable to common stockholders: | Net income (loss) per share attributable to common stockholders: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.31 | $0.19 | $(0.05) | $0.51 | $(0.97) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.29 | $0.18 | $(0.05) | $0.47 | $(0.97) |
| Weighted-average shares used in calculating net income (loss) per share attributable to common stockholders: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 165428 | 163194 | 155199 | 164316 | 103865 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 178100 | 178116 | 155199 | 178281 | 103865 |

---

------

**ASTERA LABS, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)** 

**(In thousands)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **June 30,<br>2025** | **June 30,<br>2024** |
| **Cash flows from operating activities** | | |
| Net income (loss) | $83038 | $(100541) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 77920 | 140835 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2517 | 1331 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash operating lease expense | 1522 | 1106 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants contra revenue | 2136 | 443 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of discounts on marketable securities | (4489) | (1670) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | 734 | 1526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 14491 | (13898) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (14577) | (5970) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (18474) | (5396) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 4607 | 5831 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (1592) | 10930 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability | (1963) | (1062) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 145870 | 33465 |
| **Cash flows from investing activities** |  |  |
| Purchases of property and equipment | (6562) | (2100) |
| Purchases of marketable securities | (404682) | (345756) |
| Sales and maturities of marketable securities | 343611 | 41134 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (67633) | (306722) |
| **Cash flows from financing activities** |  |  |
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions |  | 672198 |
| Payment of deferred offering costs |  | (4801) |
| Tax withholding related to net share settlements of restricted stock units |  | (20111) |
| Proceeds from exercises of stock options, net of repurchases | 778 | 1949 |
| Proceeds from employee stock purchase plan | 4345 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 5123 | 649235 |
| Net increase in cash, cash equivalents, and restricted cash | 83360 | 375978 |
| **Cash, cash equivalents, and restricted cash** |  |  |
| Beginning of the period | 80044 | 45098 |
| End of the period | $163404 | $421076 |

---

------

**ASTERA LABS, INC.** 

 **RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (Unaudited)**

 **(In thousands, except percentages and per share amounts)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **June 30,<br>2025** | **March 31,<br>2025** | **June 30,<br>2024** | **June 30,<br>2025** | **June 30,<br>2024** |
| GAAP gross profit | $145563 | $119411 | $59854 | $264974 | $110374 |
| Stock-based compensation expense upon IPO <sup>(1)</sup> |  |  |  |  | 516 |
| Stock-based compensation expense | 353 | (38) | 84 | 315 | 96 |
| Non-GAAP gross profit | $145916 | $119373 | $59938 | $265289 | $110986 |
| GAAP gross margin | 75.8% | 74.9% | 77.9% | 75.4% | 77.7% |
| Stock-based compensation expense upon IPO <sup>(1)</sup> |  |  |  |  | 0.3 |
| Stock-based compensation expense | 0.2 |  | 0.1 | 0.1 | 0.1 |
| Non-GAAP gross margin | 76.0% | 74.9% | 78.0% | 75.5% | 78.1% |
| GAAP operating income (loss) | $39774 | $11285 | $(24347) | $51059 | $(107314) |
| Stock-based compensation expense upon IPO <sup>(1)</sup> |  |  |  |  | 88873 |
| Stock-based compensation expense | 35474 | 42446 | 43067 | 77920 | 51962 |
| Employer payroll tax related to stock-based compensation from IPO <sup>(2)</sup> |  |  |  |  | 1072 |
| Non-GAAP operating income | $75248 | $53731 | $18720 | $128979 | $34593 |
| GAAP operating margin | 20.7% | 7.1% | (31.7)% | 14.5% | (75.5)% |
| Stock-based compensation expense upon IPO <sup>(1)</sup> |  |  |  |  | 62.5 |
| Stock-based compensation expense | 18.5 | 26.6 | 56.0 | 22.2 | 36.6 |
| Employer payroll tax related to stock-based compensation from IPO <sup>(2)</sup> |  |  |  |  | 0.8 |
| Non-GAAP operating margin <sup>(3)</sup> | 39.2% | 33.7% | 24.4% | 36.7% | 24.3% |
| GAAP net income (loss) | $51219 | $31819 | $(7546) | $83038 | $(100541) |
| Stock-based compensation expense upon IPO <sup>(1)</sup> |  |  |  |  | 88873 |
| Stock-based compensation expense | 35474 | 42446 | 43067 | 77920 | 51962 |
| Employer payroll tax related to stock-based compensation from IPO <sup>(2)</sup> |  |  |  |  | 1072 |
| Income tax effect <sup>(4)</sup> | (8670) | (14638) | (13296) | (23308) | (4811) |
| Non-GAAP net income | $78023 | $59627 | $22225 | $137650 | $36555 |
| **Net income (loss) per share attributable to common stockholders:** | **Net income (loss) per share attributable to common stockholders:** | **Net income (loss) per share attributable to common stockholders:** | **Net income (loss) per share attributable to common stockholders:** |  |  |
| GAAP - basic | $0.31 | $0.19 | $(0.05) | $0.51 | $(0.97) |
| GAAP - diluted | $0.29 | $0.18 | $(0.05) | $0.47 | $(0.97) |
| Non-GAAP pro forma - diluted  | $0.44 | $0.33 | $0.13 | $0.77 | $0.23 |
| **Weighted average shares used to compute net income (loss) per share attributable to common stockholders:** | **Weighted average shares used to compute net income (loss) per share attributable to common stockholders:** | **Weighted average shares used to compute net income (loss) per share attributable to common stockholders:** | **Weighted average shares used to compute net income (loss) per share attributable to common stockholders:** | **Weighted average shares used to compute net income (loss) per share attributable to common stockholders:** | **Weighted average shares used to compute net income (loss) per share attributable to common stockholders:** |
| GAAP - basic | 165428 | 163194 | 155199 | 164316 | 103865 |
| GAAP - diluted | 178100 | 178116 | 155199 | 178281 | 103865 |
| Non-GAAP pro forma - diluted <sup>(5)</sup> | 178100 | 178116 | 175279 | 178281 | 162378 |

---

____________________

------

(1) Stock-based compensation expense recognized in connection with the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.

(2) Employer payroll taxes related to the time-based vesting and settlement of RSUs, that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.

(3) Total may not sum due to rounding.

(4) Income tax effect is calculated based on the tax laws in the jurisdictions in which we operate and is calculated to exclude the impact of stock-based compensation expense and one-off discrete tax adjustments that are unrelated to our core operating performance. We no longer maintain valuation allowance for non-GAAP purposes due to our profitability on a non-GAAP basis. For the three months ended June 30, 2025, March 31, 2025, and June 30, 2024, the non-GAAP tax expense rate was approximately 9%, 7%, and 23%, respectively. For the six months ended June 30, 2025 and 2024, the non-GAAP tax expense rate was approximately 8% and 23%, respectively.

(5) We present the non-GAAP pro-forma weighted average shares to provide meaningful supplemental information of comparable shares for each period presented. The non-GAAP pro forma weighted average shares is calculated as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **June 30,<br>2025** | **March 31,<br>2025** | **June 30,<br>2024** | **June 30,<br>2025** | **June 30,<br>2024** |
| Shares used to compute GAAP net income (loss) per share attributable to common stockholders - diluted | 178100 | 178116 | 155199 | 178281 | 103865 |
| Weighted average effect of the assumed conversion of redeemable convertible preferred stock from the beginning of the periods |  |  |  |  | 40451 |
| Effect of dilutive equivalent shares |  |  | 20080 |  | 18062 |
| Shares used to compute non-GAAP pro forma net income per share - diluted | 178100 | 178116 | 175279 | 178281 | 162378 |

---

------

**ASTERA LABS, INC.,** 

 **RECONCILIATION OF GAAP TO NON-GAAP OUTLOOK (Unaudited)**

 **(In millions, except percentages and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **Outlook for Three Months Ending September 30, 2025** | **Outlook for Three Months Ending September 30, 2025** |
| | **Low** | **High** |
| GAAP gross margin | 75.0% | 75.0% |
| Stock-based compensation expense  |  |  |
| Non-GAAP gross margin | 75.0% | 75.0% |
| GAAP operating expense | $116 | $120 |
| Stock-based compensation expense | 40 | 40 |
| Non-GAAP operating expense | $76 | $80 |
| GAAP tax rate | 10% | 10% |
| Income tax effect | 10 | 10 |
| Non-GAAP tax rate | 20% | 20% |
| GAAP EPS - diluted | $0.23 | $0.24 |
| Stock-based compensation expense and income tax effect | 0.15 | 0.15 |
| Non-GAAP EPS - diluted | $0.38 | $0.39 |

---

**ASTERA LABS, INC.** 

 **SUPPLEMENTAL FINANCIAL INFORMATION** 

**STOCK-BASED COMPENSATION EXPENSE (Unaudited)**

 **(In thousands)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **June 30,<br>2025** | **March 31,<br>2025** | **June 30,<br>2024** | **June 30,<br>2025** | **June 30,<br>2024** |
| Cost of revenue | $353 | $(38) | $84 | $315 | $612 |
| Research and development | 17852 | 19186 | 12971 | 37038 | 42978 |
| Sales and marketing | 9194 | 12319 | 15758 | 21513 | 65016 |
| General and administrative | 8075 | 10979 | 14254 | 19054 | 32229 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense <sup>(1)</sup> | $35474 | $42446 | $43067 | $77920 | $140835 |

---

____________________

(1) Stock-based compensation expense recognized during the six months ended June 30, 2024 included $88.9 million of cumulative stock-based compensation expense related to the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.

<br>